John A Orwin
CIK 1477384 · PRESIDENT & CEO · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.77M
Companies
9
Total Filings
93
Lifetime Open-Market Net
-$8.30M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRAX | Director | 16,695 | $41.85 | $698.7K | $0 | 4 | 2026-06-17 |
| ANAB | Director | 16,695 | $52.11 | $870.0K | $0 | 10 | 2026-06-17 |
| TVTX | Director | 39,375 | $55.91 | $2.20M | $0 | 6 | 2026-05-21 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 4 | 2025-08-19 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $56.7K | 12 | 2023-12-15 |
| Atreca, Inc. (BCEL) Delisted | President & CEO | 100,492 | $0.15 | $15.1K | $39.6K | 8 | 2023-02-13 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 11,875 | — | — | $0 | 4 | 2020-05-19 |
| Relypsa Inc (RLYP) Delisted | President & CEO | 0 | — | — | -$3.61M | 12 | 2016-09-02 |
| AFFYMAX INC (AFFY) Delisted | CEO | 108,000 | — | — | -$4.78M | 18 | 2013-02-05 |
Recent Filings · Page 4 of 10
93 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-12 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2021-12-28 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-13 | Atreca, Inc. (BCEL) Delisted | Grant (A) | +115,400 | $0 | EDGAR |
| 2021-05-18 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2021-05-18 | Seagen Inc. (SGEN) Delisted | Grant (A) | +1,402 | $0 | EDGAR |
| 2021-01-29 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-19 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2020-05-19 | Seagen Inc. (SGEN) Delisted | Grant (A) | +1,335 | $0 | EDGAR |
| 2020-03-19 | Atreca, Inc. (BCEL) Delisted | Buy (P) | +6,000 | $76.7K | EDGAR |
| 2020-02-28 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.